½ÃÀ庸°í¼­
»óǰÄÚµå
1762564

¼¼°èÀÇ Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¾×(HPL) ½ÃÀå : ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Çâ, ¾÷°è ºÐ¼®(¿ëµµº°, À¯Çüº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°), ¿¹Ãø(2025-2034³â)

Human Platelet Lysate Market Size, Share, Trends, & Industry Analysis Report: By Application (Research and Therapeutic), By Type, By End Use, By Region - Market Forecast, 2025-2034

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Polaris Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 113 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é, Àü ¼¼°è Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¾×(HPL) ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö 7,848¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÅëÂû·Â°ú ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¾×(HPL)Àº »ý¹° ÀÇÇÐ ¿¬±¸ ¹× Àç»ý ÀÇÇÐ ºÐ¾ß¿¡¼­ ¸Å¿ì Áß¿äÇÑ ¼ººÐÀ¸·Î µîÀåÇÏ¿© ¼¼Æ÷ ¹è¾ç ±â¼ú ¹× Ä¡·á ¿ëµµ¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. Àΰ£ Ç÷¼ÒÆÇ¿¡¼­ ÃßÃâÇÑ ÀÌ ´ÙÀç´Ù´ÉÇÑ Á¦Ç°Àº ¼Ò ÅÂ¾Æ Ç÷û(FBS)°ú °°Àº ±âÁ¸ ¼¼Æ÷ ¹è¾ç º¸ÃæÁ¦¿¡ ºñÇØ ¸¹Àº ÀÌÁ¡À» Á¦°øÇϸç, HPL¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ¾ÈÀü¼º, È¿À²¼º, À±¸®Àû °í·Á »çÇ× µî ¿©·¯ °¡Áö ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù.

Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¾×(HPL) ½ÃÀåÀº °úÇÐÀÇ ¹ßÀü°ú ½ÇÁ¦ ÀÇ·á ¼ö¿ä¿¡ ÀÇÇØ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ¼¼°è °¢±¹ Á¤ºÎ´Â ÀÚ±Ý Áö¿ø, º¸Á¶±Ý, ±ÔÁ¦Àû Áö¿øÀ» ÅëÇØ Àç»ýÀÇ·á¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ³ë·ÂÀº °úÇÐÀÚµé°ú ±â¾÷µéÀÌ Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¾×¿¡ ÀÇÁ¸ÇÏ¿© ¼¼Æ÷¸¦ ¾ÈÀüÇϰí È¿°úÀûÀ¸·Î Áõ½Ä ¹× Áõ½Ä½ÃŰ´Â »õ·Î¿î Ä¡·á¹ýÀ» ¸ð»öÇÏ´Â µ¥ ÈûÀ» ½Ç¾îÁÖ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áö¿øÀ¸·Î ÀÌ ºÐ¾ß¿¡ ´ëÇÑ ½Å·Ú°¡ ½×¿© Áٱ⼼Æ÷ Ä¡·á¹ýÀÌ ´õ ºü¸£°Ô ¹ßÀüÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ÆÄŲ½¼º´, °ñ°üÀý¿°, Å»¸ðÁõ(³²¼ºÇü Å»¸ðÁõ) µî ¸¸¼º Áúȯ Áõ°¡°¡ HPL ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áúº´Àº Àα¸ÀÇ °í·ÉÈ­¿Í ¶óÀÌÇÁ½ºÅ¸ÀÏÀÇ º¯È­·Î ÀÎÇØ ´õ¿í º¸ÆíÈ­µÇ°í ÀÖ½À´Ï´Ù. ÇöÀç ÀÌ·¯ÇÑ ÁúȯÀÇ ´ëºÎºÐÀº Ä¡·á ¿É¼ÇÀÌ Á¦ÇÑÀûÀ̱⠶§¹®¿¡ ÀÇ»ç¿Í ¿¬±¸ÀÚµéÀº Àç»ýÀÇÇÐÀ¸·Î ´«À» µ¹¸®°í ÀÖ½À´Ï´Ù. Ç÷¼ÒÆÇ ¿ëÇØ¾×Àº ¼Õ»óµÈ Á¶Á÷À» º¹±¸Çϰí Àç»ýÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â õ¿¬ ¼ºÀå ÀÎÀÚ¸¦ Æ÷ÇÔÇϰí Àֱ⠶§¹®¿¡ ÀÌ·¯ÇÑ »õ·Î¿î Ä¡·á¹ý¿¡¼­ ´õ ÀÚÁÖ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

±ÔÁ¦ ȯ°æÀº HPL ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¸¹Àº ±¹°¡ÀÇ ±ÔÁ¦ ±â°üÀº À±¸®ÀûÀ¸·Î Á¶´ÞµÈ ¾ÈÀüÇÑ ¼¼Æ÷ ¹è¾ç º¸ÃæÁ¦ÀÇ »ç¿ëÀ» Æ÷ÇÔÇÏ¿© º¸´Ù ¾ÈÀüÇϰí Åõ¸íÇÑ ¿¬±¸ °üÇàÀ» ¿ËÈ£Çϰí ÀÖ½À´Ï´Ù. ¿ì¼öÇÑ ¾ÈÀü¼º°ú À±¸®Àû ÇÁ·ÎÆÄÀÏÀ» °®Ãá HPLÀº ÀÌ·¯ÇÑ ±ÔÁ¦ ¿ä°ÇÀ» ÃæÁ·Çϰí ÀÓ»ó½ÃÇè ¹× Ä¡·á ¿ëµµÀÇ ½ÂÀÎ ÀýÂ÷¸¦ ¿ëÀÌÇÏ°Ô ÇÕ´Ï´Ù.

Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¾×(HPL) ½ÃÀå : ºÐ¼® °³¿ä

À¯Çüº°·Î´Â ÇìÆÄ¸° ÇÁ¸® ±â¹Ý Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØÁ¦ ºÎ¹®ÀÌ Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØÁ¦ ½ÃÀå Á¡À¯À²À» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ±ÔÁ¦ Áؼö, ¾ÈÀü¼º, ÀÓ»ó ¹× ¿¬±¸ ȯ°æ¿¡¼­ÀÇ ±¤¹üÀ§ÇÑ Àû¿ë¼º¿¡¼­ À¯¸®Çϱ⠶§¹®ÀÔ´Ï´Ù. ÇìÆÄ¸°À» ÇÔÀ¯ÇÏÁö ¾ÊÀº HPLÀº ¼¼Æ÷ ¹è¾ç ¹× Àç»ý ÀÇÇп¡¼­ Áß¿äÇÑ ¼ººÐÀ¸·Î ºÎ»óÇϰí ÀÖÀ¸¸ç, ±âÁ¸ÀÇ ¼ºÀå º¸Á¶Á¦¸¦ ´ëüÇÒ ¼ö ÀÖ´Â ¹«Ç÷û ´ë¾ÈÀ¸·Î ¶°¿À¸£°í ÀÖ½À´Ï´Ù.

¿ëµµº°·Î´Â ¿¬±¸¿ë ºÐ¾ß°¡ ¿¹Ãø ±â°£ µ¿¾È 3.5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ·¯ÇÑ ºü¸¥ ¼ºÀåÀº ¼¼Æ÷ ¹è¾ç ¿¬±¸¿¡¼­ ¼Ò ÅÂ¾Æ Ç÷ûÀ» ´ëüÇÒ ¼ö ÀÖ´Â ¿ì¼öÇÑ ´ë¾ÈÀ¸·Î Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¾×ÀÇ »ç¿ëÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¾×Àº Áß°£¿± Áٱ⼼Æ÷, ¸é¿ª¼¼Æ÷ ¹× ±âŸ Àΰ£ À¯·¡ ¼¼Æ÷ÀÇ Áõ½Ä¿¡ ÇʼöÀûÀÎ ¼ºÀåÀÎÀÚ¸¦ dzºÎÇÏ°Ô ÇÔÀ¯Çϰí ÀÖ¾î ÀüÀÓ»ó ¹× Áß°³¿¬±¸¿¡ ÀÌ»óÀûÀÔ´Ï´Ù.

2024³â Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¾×(HPL) ½ÃÀåÀÇ ¸ÅÃâ Á¡À¯À²Àº ºÏ¹Ì°¡ ¾ÐµµÀûÀ¸·Î ³ô¾Ò½À´Ï´Ù. ºÏ¹Ì´Â Áٱ⼼Æ÷ ¿¬±¸ÀÇ Áß½ÉÁö·Î¼­, ÇüÁúÀüȯ Áٱ⼼Æ÷, À¯µµ¸¸´ÉÁٱ⼼Æ÷(iPSC), ¼ºÃ¼Áٱ⼼Æ÷¸¦ Æ÷ÇÔÇÑ Áٱ⼼Æ÷ ¿¬±¸ÀÇ °ÅÁ¡À̸ç, HPLÀº ¹ß»ý °úÁ¤ ¿¬±¸ ¹× Ä¡·á Àû¿ëÀ» À§ÇØ ÀÌ·¯ÇÑ ¼¼Æ÷¸¦ ¹è¾çÇϰí Áõ½Ä½ÃŰ´Â µ¥ »ç¿ëµË´Ï´Ù. ¹Ì±¹¿¡¼­´Â Áٱ⼼Æ÷ ¹è¾çÀº Àç»ýÀÇ·á ¹× »ýÀÇÇÐ ¿¬±¸ ºÐ¾ß¿¡¼­ ±âº» ¿ä¼Ò·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

À¯·´ÀÇ Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¾×(HPL) ½ÃÀåÀº ÀÌ Áö¿ªÀÌ »ý¹°ÀÇÇÐ ¿¬±¸¿¡ ÁßÁ¡À» µÎ°í ÀÖ°í, Àç»ýÀÇ·á ºÐ¾ß°¡ È®´ëµÇ°í ÀÖÀ¸¸ç, ±ÔÁ¦ ȯ°æÀÌ ¾çÈ£ÇÑ ¸¸Å­ Å« ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù.

¼¼°è ÁÖ¿ä ½ÃÀå ±â¾÷À¸·Î´Â Merck KGaA, Compass Biomedical Inc, PL BioScience, AventaCell BioMedical Corp, Mill Creek Lifesciences LLC, Stem Cell Technologies Inc, Zen Bio, Inc, Sclavo Diagnostics International Sr, Lifescience Group Limited, Trinova Biochem GmbH µîÀÌ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ºÐ¼® ¹æ¹ý

Á¦4Àå ½ÃÀå ÀλçÀÌÆ®

  • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¾× : ½ÃÀå ÇöȲ
  • ¹ë·ùüÀÎ ºÐ¼®
    • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¾×½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀΰú ±âȸ
    • ¼ºÀå ¾ïÁ¦¿äÀΰú °úÁ¦
  • PorterÀÇ Five Forces ºÐ¼®
    • ´ëüǰÀÇ À§Çù(Àú)
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù(Àú-Áß)
    • ¹ÙÀ̾îÀÇ ±³¼··Â(Áß)
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â(Áß-°í)
    • °æÀï ±â¾÷°£ °æÀï °ü°è(Áß-°í)
  • PESTLE ºÐ¼®
  • COVID-19ÀÇ ¿µÇ⠺м®°ú ¾÷°è µ¿Çâ

Á¦5Àå Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¾×½ÃÀå Æò°¡ : À¯Çüº°

  • ¼­·Ð
  • Heparin Based Human Platelet Lysate
  • Heparin Free Based Human Platelet Lysate

Á¦6Àå Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¾×½ÃÀå Æò°¡ : ¿ëµµº°

  • ¼­·Ð
  • ¿¬±¸¿ë
  • Ä¡·á¿ë

Á¦7Àå Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¾×½ÃÀå Æò°¡ : ÃÖÁ¾»ç¿ëÀÚº°

  • ¼­·Ð
  • Á¦¾à ±â¾÷ ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • Çмú¿¬±¸±â°ü
  • ±âŸ

Á¦8Àå Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¾×½ÃÀå ºÐ¼® : Áö¿ªº°

  • ¼­·Ð
  • ºÏ¹Ì
    • ºÏ¹ÌÀÇ Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¾×½ÃÀå : À¯Çüº°
    • ºÏ¹ÌÀÇ Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¾×½ÃÀå : ¿ëµµº°
    • ÃÖÁ¾»ç¿ëÀÚº°
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • À¯·´ÀÇ Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¾×½ÃÀå : À¯Çüº°
    • À¯·´ÀÇ Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¾×½ÃÀå : ¿ëµµº°
    • ÃÖÁ¾»ç¿ëÀÚº°
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¾×½ÃÀå : À¯Çüº°
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¾×½ÃÀå : ¿ëµµº°
    • ÃÖÁ¾»ç¿ëÀÚº°
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • ¸»·¹À̽þÆ
    • Àεµ³×½Ã¾Æ
    • Çѱ¹
    • È£ÁÖ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¾×½ÃÀå : À¯Çüº°
    • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¾×½ÃÀå : ¿ëµµº°
    • ÃÖÁ¾»ç¿ëÀÚº°
    • ¸ß½ÃÄÚ
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¾×½ÃÀå : À¯Çüº°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¾×½ÃÀå : ¿ëµµº°
    • ÃÖÁ¾»ç¿ëÀÚº°
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï ±¸µµ

  • ½ÃÀå ÁÖ¿ä ±â¾÷ : ºÐ·ù
  • Àü·«Àû ÇÁ·¹ÀÓ¿öÅ©
  • º¥´õ ±¸µµ
  • Àü·« ºÐ·ù
    • ÃÖ±Ù µ¿Çâ

Á¦10Àå ±â¾÷ °³¿ä

  • Merck KGaA
  • Compass Biomedical, Inc.
  • PL BioScience GmbH
  • AventaCell BioMedical Corp.
  • Mill Creek Life Sciences
  • Stem Cell Technology, Inc.
  • ZenBio, Inc.
  • SCLAVO Diagnostics International
  • Lifescience Group Limited
  • Trinova Biochem GmbH
LSH 25.07.11

The global human platelet lysate market size is expected to reach USD 78.48 million by 2034, according to a new study by Polaris Market Research. The report "Human Platelet Lysate Market Size, Share, Trends, & Industry Analysis Report: By Application (Research and Therapeutic), By Type, By End Use, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Human Platelet Lysate (HPL) has emerged as a pivotal component in the field of biomedical research and regenerative medicine, revolutionizing cell culture techniques and therapeutic applications. This versatile product, derived from human blood platelets, offers numerous advantages over traditional cell culture supplements such as Fetal Bovine Serum (FBS). The growing demand for HPL can be attributed to several driving factors, including its safety, efficiency, and ethical considerations.

The human platelet lysate (HPL) market is growing due to scientific advancements and real-world healthcare needs. Governments across the world are investing heavily in regenerative medicine by providing funding, grants, and regulatory support. These efforts are encouraging scientists and companies to explore new treatments that rely on human platelet lysate to grow and expand cells safely and effectively. This support has helped build trust in the field and led to faster progress in stem cell therapy. Additionally, the rising number of chronic diseases such as Parkinson's disease, osteoarthritis, and hair loss (androgenetic alopecia) is driving the HPL market growth. These conditions are becoming more common due to aging populations and changing lifestyles. Many of them currently have limited treatment options, which is why doctors and researchers are turning to regenerative medicine. Platelet lysate is being used more often in these new therapies as it contains natural growth factors that help repair and regenerate damaged tissues.

The regulatory landscape has contributed to the growth of the HPL market. Regulatory bodies in many countries have been advocating for safer and more transparent research practices, which include the use of ethically sourced and safe cell culture supplements. HPL, with its favorable safety and ethical profiles, aligns with these regulatory requirements, easing the approval processes for clinical trials and therapeutic applications.

Human Platelet Lysate Market Report Highlights

By type, the heparin free based human platelet lysate segment dominated the human platelet lysate market share, due to its advantages in regulatory compliance, safety, and broader applicability in clinical and research settings. Heparin-free HPL has emerged as a critical component in cell culture and regenerative medicine, offering a serum-free alternative to traditional growth supplements.

By application, the research segment is expected to register a CAGR of 3.5% during the forecast period. The rapid growth is attributed to the growing use of human platelet lysate as a superior alternative to fetal bovine serum in cell culture research. It provides rich growth factors essential for expanding mesenchymal stem cells, immune cells, and other human-derived cells, making it ideal for preclinical and translational studies.

North America dominated the global human platelet lysate market revenue share in 2024. North America is a hub for stem cell research, encompassing pluripotent stem cells, induced pluripotent stem cells (iPSCs), and adult stem cells. HPL is employed to culture and expand these cells for research into developmental processes and therapeutic applications. In the US, stem cell culture serves as a fundamental element in the realms of regenerative medicine and biomedical research.

The human platelet lysate market in Europe is experiencing significant growth, owing to the region's strong emphasis on biomedical research, expanding regenerative medicine sector, and favorable regulatory landscape.

A few global key market players are Merck KGaA; Compass Biomedical Inc.; PL BioScience; AventaCell BioMedical Corp; Mill Creek Lifesciences LLC; Stem Cell Technologies Inc; Zen Bio, Inc.; Sclavo Diagnostics International Sr; Lifescience Group Limited; and Trinova Biochem GmbH.

Polaris Market Research has segmented the human platelet lysate market report on the basis of type, application, end use, and region:

By Type Outlook (Revenue, USD Million, 2020-2034)

Heparin Based HPL

Heparin Free HPL

By Application Outlook (Revenue, USD Million, 2020-2034)

Research

Therapeutic

By End Use Outlook (Revenue, USD Million, 2020-2034)

Pharmaceutical & Biotechnological Companies

Academic & Research Institutes

Others

By Regional Outlook (Revenue, USD Million, 2020-2034)

North America

US

Canada

Mexico

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

Malaysia

Australia

Indonesia

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

Rest of Middle East & Africa

Latin America

Brazil

Argentina

Rest of Latin America

Table of Contents

Chapter 1. Introduction

  • 1.1 Report Description
    • 1.1.1 Objective of the Study
    • 1.1.2 Market Scope
    • 1.1.3 Assumptions
  • 1.2 Stakeholders

Chapter 2. Research Methodology

  • 2.1 Research Methodology
  • 2.2 Research Scope and Assumptions
  • 2.3 Information Procurement
    • 2.3.1 Purchased Database
    • 2.3.2 Internal Database
    • 2.3.3 Secondary Sources
    • 2.3.4 Third Party Perspective
    • 2.3.5 Primary Research
  • 2.4 Information Analysis
    • 2.4.1 Data Analysis Models
  • 2.5 Market Formulation and Data Visualization
  • 2.6 Data Validation and Publishing (Secondary Sources)

Chapter 3. Executive Summary

Chapter 4. Market Insights

  • 4.1 Human Platelet Lysate - Industry snapshot
  • 4.2 Human Platelet Lysate Market - Value Chain Analysis
    • 4.2.1 Human Platelet Lysate Market Dynamics
    • 4.2.2 Drivers and Opportunities
      • 4.2.2.1 Increasing in the research and development (R&D) activities of stem cell therapy by leading companies and governments
      • 4.2.2.2 Increasing prevalence of chronic diseases such as Parkinson's disease, osteoarthritis, androgenetic alopecia and others
    • 4.2.3 Restraints and Challenges
      • 4.2.3.1 High cost and increased risk of transmission of infectious communicable diseases
  • 4.3 Human Platelet Lysate Market - Porter's Five Forces
    • 4.3.1 Threat of Substitutes: (Low)
    • 4.3.2 Threat of New Entrants: (Low to Moderate)
    • 4.3.3 Bargaining power of buyers: (Moderate)
    • 4.3.4 Bargaining power of suppliers: (Moderate to High)
    • 4.3.5 Competitive Rivalry: (Moderate to High)
  • 4.4 Human Platelet Lysate Market - PESTLE Analysis
  • 4.5 Covid-19 Impact Analysis & Industry Trends

Chapter 5. Human Platelet Lysate Market Assessment by Type

  • 5.1 Introduction
  • 5.2 Heparin Based Human Platelet Lysate
  • 5.3 Heparin Free Based Human Platelet Lysate

Chapter 6. Human Platelet Lysate Market Assessment by Application

  • 6.1 Introduction
  • 6.2 Research
  • 6.3 Therapeutic

Chapter 7. Human Platelet Lysate Market Assessment by End-User

  • 7.1 Introduction
  • 7.2 Pharmaceutical & Biotechnological Companies
  • 7.3 Academic & Research Institutes
  • 7.4 Others

Chapter 8. Human Platelet Lysate Market Assessment by Region

  • 8.1 Introduction
  • 8.2 Human Platelet Lysate Market - North America
    • 8.2.1 North America Human Platelet Lysate, By Type
    • 8.2.2 North America Human Platelet Lysate, By Application
    • 8.2.3 North America Human Platelet Lysate Market, By End-User
    • 8.2.4 Human Platelet Lysate Market - U.S.
      • 8.2.4.1 U.S. Human Platelet Lysate, By Type
      • 8.2.4.2 U.S. Human Platelet Lysate, By Application
      • 8.2.4.3 U.S. Human Platelet Lysate Market, By End-User
    • 8.2.5 Human Platelet Lysate Market - Canada
      • 8.2.5.1 Canada Human Platelet Lysate, By Type
      • 8.2.5.2 Canada Human Platelet Lysate, By Application
      • 8.2.5.3 Canada Human Platelet Lysate Market, By End-User
  • 8.3 Human Platelet Lysate Market - Europe
    • 8.3.1 Europe Human Platelet Lysate, By Type
    • 8.3.2 Europe Human Platelet Lysate, By Application
    • 8.3.3 Europe Human Platelet Lysate Market, By End-User
    • 8.3.4 Human Platelet Lysate Market - France
      • 8.3.4.1 France Human Platelet Lysate, By Type
      • 8.3.4.2 France Human Platelet Lysate, By Application
      • 8.3.4.3 France Human Platelet Lysate Market, By End-User
    • 8.3.5 Human Platelet Lysate Market - Germany
      • 8.3.5.1 Germany Human Platelet Lysate, By Type
      • 8.3.5.2 Germany Human Platelet Lysate, By Application
      • 8.3.5.3 Germany Human Platelet Lysate Market, By End-User
    • 8.3.6 Human Platelet Lysate Market - UK
      • 8.3.6.1 U.K. Human Platelet Lysate, By Type
      • 8.3.6.2 U.K. Human Platelet Lysate, By Application
      • 8.3.6.3 U.K. Human Platelet Lysate Market, By End-User
    • 8.3.7 Human Platelet Lysate Market - Italy
      • 8.3.7.1 Italy Human Platelet Lysate, By Type
      • 8.3.7.2 Italy Human Platelet Lysate, By Application
      • 8.3.7.3 Italy Human Platelet Lysate Market, By End-User
    • 8.3.8 Human Platelet Lysate Market - Netherlands
      • 8.3.8.1 Netherlands Human Platelet Lysate, By Type
      • 8.3.8.2 Netherlands Human Platelet Lysate, By Application
      • 8.3.8.3 Netherlands Human Platelet Lysate Market, By End-User
    • 8.3.9 Human Platelet Lysate Market - Spain
      • 8.3.9.1 Spain Human Platelet Lysate, By Type
      • 8.3.9.2 Spain Human Platelet Lysate, By Application
      • 8.3.9.3 Spain Human Platelet Lysate Market, By End-User
    • 8.3.10 Human Platelet Lysate Market - Russia
      • 8.3.10.1 Russia Human Platelet Lysate, By Type
      • 8.3.10.2 Russia Human Platelet Lysate, By Application
      • 8.3.10.3 Russia Human Platelet Lysate Market, By End-User
    • 8.3.11 Human Platelet Lysate Market - Rest of Europe
      • 8.3.11.1 Rest of Europe Human Platelet Lysate, By Type
      • 8.3.11.2 Rest of Europe Human Platelet Lysate, By Application
      • 8.3.11.3 Rest of Europe Human Platelet Lysate Market, By End-User
  • 8.4 Human Platelet Lysate Market - Asia Pacific
    • 8.4.1 Asia Pacific Human Platelet Lysate, By Type
    • 8.4.2 Asia Pacific Human Platelet Lysate, By Application
    • 8.4.3 Asia Pacific Human Platelet Lysate Market, By End-User
    • 8.4.4 Human Platelet Lysate Market - Japan
      • 8.4.4.1 Japan Human Platelet Lysate, By Type
      • 8.4.4.2 Japan Human Platelet Lysate, By Application
      • 8.4.4.3 Japan Human Platelet Lysate Market, By End-User
    • 8.4.5 Human Platelet Lysate Market - China
      • 8.4.5.1 China Human Platelet Lysate, By Type
      • 8.4.5.2 China Human Platelet Lysate, By Application
      • 8.4.5.3 China Human Platelet Lysate Market, By End-User
    • 8.4.6 Human Platelet Lysate Market - India
      • 8.4.6.1 India Human Platelet Lysate, By Type
      • 8.4.6.2 India Human Platelet Lysate, By Application
      • 8.4.6.3 India Human Platelet Lysate Market, By End-User
    • 8.4.7 Human Platelet Lysate Market - Malaysia
      • 8.4.7.1 Malaysia Human Platelet Lysate, By Type
      • 8.4.7.2 Malaysia Human Platelet Lysate, By Application
      • 8.4.7.3 Malaysia Human Platelet Lysate Market, By End-User
    • 8.4.8 Human Platelet Lysate Market - Indonesia
      • 8.4.8.1 Indonesia Human Platelet Lysate, By Type
      • 8.4.8.2 Indonesia Human Platelet Lysate, By Application
      • 8.4.8.3 Indonesia Human Platelet Lysate Market, By End-User
    • 8.4.9 Human Platelet Lysate Market - South Korea
      • 8.4.9.1 South Korea Human Platelet Lysate, By Type
      • 8.4.9.2 South Korea Human Platelet Lysate, By Application
      • 8.4.9.3 South Korea Human Platelet Lysate Market, By End-User
    • 8.4.10 Human Platelet Lysate Market - Australia
      • 8.4.10.1 Australia Human Platelet Lysate, By Type
      • 8.4.10.2 Australia Human Platelet Lysate, By Application
      • 8.4.10.3 Australia Human Platelet Lysate Market, By End-User
    • 8.4.11 Human Platelet Lysate Market - Rest of APAC
      • 8.4.11.1 Rest of APAC Human Platelet Lysate, By Type
      • 8.4.11.2 Rest of APAC Human Platelet Lysate, By Application
      • 8.4.11.3 Rest of APAC Human Platelet Lysate Market, By End-User
  • 8.5 Human Platelet Lysate Market - Latin America
    • 8.5.1 Latin America Human Platelet Lysate, By Type
    • 8.5.2 Latin America Human Platelet Lysate, By Application
    • 8.5.3 Latin America Human Platelet Lysate Market, By End-User
    • 8.5.4 Human Platelet Lysate Market - Mexico
      • 8.5.4.1 Mexico Human Platelet Lysate, By Type
      • 8.5.4.2 Mexico Human Platelet Lysate, By Application
      • 8.5.4.3 Mexico Human Platelet Lysate Market, By End-User
    • 8.5.5 Human Platelet Lysate Market - Brazil
      • 8.5.5.1 Brazil Human Platelet Lysate, By Type
      • 8.5.5.2 Brazil Human Platelet Lysate, By Application
      • 8.5.5.3 Brazil Human Platelet Lysate Market, By End-User
    • 8.5.6 Human Platelet Lysate Market - Argentina
      • 8.5.6.1 Argentina Human Platelet Lysate, By Type
      • 8.5.6.2 Argentina Human Platelet Lysate, By Application
      • 8.5.6.3 Argentina Human Platelet Lysate Market, By End-User
    • 8.5.7 Human Platelet Lysate Market - Rest of Latin America
      • 8.5.7.1 Rest of Latin America Human Platelet Lysate, By Type
      • 8.5.7.2 Rest of Latin America Human Platelet Lysate, By Application
      • 8.5.7.3 Rest of Latin America Human Platelet Lysate Market, By End-User
  • 8.6 Human Platelet Lysate Market - Middle East Africa
    • 8.6.1 Middle East Africa Human Platelet Lysate, By Type
    • 8.6.2 Middle East Africa Human Platelet Lysate, By Application
    • 8.6.3 Middle East Africa Human Platelet Lysate Market, By End-User
    • 8.6.4 Human Platelet Lysate Market - Saudi Arabia
      • 8.6.4.1 Saudi Arabia Human Platelet Lysate, By Type
      • 8.6.4.2 Saudi Arabia Human Platelet Lysate, By Application
      • 8.6.4.3 Saudi Arabia Human Platelet Lysate Market, By End-User
    • 8.6.5 Human Platelet Lysate Market - UAE
      • 8.6.5.1 UAE Human Platelet Lysate, By Type
      • 8.6.5.2 UAE Human Platelet Lysate, By Application
      • 8.6.5.3 UAE Human Platelet Lysate Market, By End-User
    • 8.6.6 Human Platelet Lysate Market - South Africa
      • 8.6.6.1 South Africa Human Platelet Lysate, By Type
      • 8.6.6.2 South Africa Human Platelet Lysate, By Application
      • 8.6.6.3 South Africa Human Platelet Lysate Market, By End-User
    • 8.6.7 Human Platelet Lysate Market - Rest of MEA
      • 8.6.7.1 Rest of MEA Human Platelet Lysate, By Type
      • 8.6.7.2 Rest of MEA Human Platelet Lysate, By Application
      • 8.6.7.3 Rest of MEA Human Platelet Lysate Market, By End-User

Chapter 9. Competitive Landscape

  • 9.1 Key Market Players: Categorization
  • 9.2 Strategy Framework
  • 9.3 Vendor Landscape
  • 9.4 Strategies Categorization
    • 9.4.1 Recent Development

Chapter 10. Company Profiles

  • 10.1 Merck KGaA
    • 10.1.1 Business Overview
    • 10.1.2 Financial Snapshot
      • 10.1.2.1 Revenue by Market Segment
      • 10.1.2.2 Revenue by Region
    • 10.1.3 Products and Services
  • 10.2 Compass Biomedical, Inc.
    • 10.2.1 Business Overview
    • 10.2.2 Products and Services
  • 10.3 PL BioScience GmbH
    • 10.3.1 Business Overview
    • 10.3.2 Products and Services
    • 10.3.3 Recent Developments
  • 10.4 AventaCell BioMedical Corp.
    • 10.4.1 Business Overview
    • 10.4.2 Products and Services
  • 10.5 Mill Creek Life Sciences
    • 10.5.1 Business Overview
    • 10.5.2 Products and Services
  • 10.6 Stem Cell Technology, Inc.
    • 10.6.1 Business Overview
    • 10.6.2 Products and Services
    • 10.6.3 Recent Developments
  • 10.7 ZenBio, Inc.
    • 10.7.1 Business Overview
    • 10.7.2 Products and Services
  • 10.8 SCLAVO Diagnostics International
    • 10.8.1 Business Overview
    • 10.8.2 Products and Services
  • 10.9 Lifescience Group Limited
    • 10.9.1 Business Overview
    • 10.9.2 Products and Services
  • 10.10 Trinova Biochem GmbH
    • 10.10.1 Business Overview
    • 10.10.2 Products and Services
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦